Eye DiseasesNCT03553017
The EXPLORE Study - The Use of Binocular OCT Imaging for the Assessment of Ocular Disease
An observational study of Eye Diseases and Eye Infections, run by University College, London at 1 site in United Kingdom.
Trial summary
Optical coherence tomography (OCT) is an imaging modality, first described in 1991, that provides cross-sectional images of the eye in a non-invasive manner. OCT is analogous to ultrasonography but measures the "echoes" of light waves rather than sound and, as a result, generates extremely high-resolution images (~5… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Eye Diseases, Eye Infections, Eye Inflammation
- What is being tested?
- Binocular OCT
- Type of treatment
- Medical device
- How many people
- 70 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 22 May 2018to 1 Mar 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
Who may be able to join
- Presence of ocular disease that can be imaged using optical coherence tomography
- Male or female, aged 18 years or older
- Ability to understand nature/purpose of the study and to provide informed consent
- Ability to undergo binocular OCT imaging
- Ability to follow instructions and complete the study
- Ability to speak English
Who cannot join
- Optical media opacity sufficient to preclude adequate ocular imaging with OCT
- Hearing impairment sufficient to interfere with hearing instructions
- Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Single-Site Non-Interventional Exploratory Study Using a Prototype Binocular Optical Coherence Tomography System for Imaging of Ocular Disease
Optical coherence tomography (OCT) is an imaging modality, first described in 1991, that provides cross-sectional images of the eye in a non-invasive manner. OCT is analogous to ultrasonography but measures the "echoes" of light waves rather than sound and, as a result, generates extremely high-resolution images (~5 μm axial resolution). Although OCT has already proven revolutionary in ophthalmology, current OCT systems are large, expensive, and require skilled personnel for image acquisition and interpretation. Furthermore, current OCT systems are limited to examination of specific regions of single eyes - for example, separate devices are typically required for anterior segment (e.g., cornea) versus posterior segment (e.g., retina) imaging. A new form of OCT imaging has recently been developed - so-called "binocular" optical coherence tomography (OCT) (Envision Diagnostics, Inc., California).1,2 Binocular OCT addresses many of the short-comings of conventional OCT devices.
Binocular OCT extends the application of OCT devices beyond that of simple, cross- sectional imaging to a diverse array of diagnostic tests. The binocular design also removes the need for additional personnel to perform testing (i.e., the device can be self-operated in an automated manner), and allows for novel testing to be performed that is not possible with monocular imaging. In particular, binocular OCT devices have the potential to perform automated, quantitative pupillary measurements - an entirely novel application for this imaging modality, plus also adds a number of unique capabilities. In particular, binocular OCT removes the need for additional personnel to acquire the images by enabling patients to align the optical axes of the instrument with the optical axes of their own eyes. The system also employs recently developed "swept-source" lasers as its light source, allowing it to see deeper into the eye than conventional OCT systems. Finally, binocular OCT systems allow image capture from both eyes at the same time. This "simultaneous" ocular imaging extends the range of diagnostic testing possible, allowing for features such as pupillometry and ocular motility.
Read more
The greatly increased range of imaging for these lasers enables the entire depth of eye tissue to be captured in just a few sequences of images - so- called "whole eye" OCT or "OCT ophthalmoscopy".
In this study, the investigators aim to explore the unique imaging features of the binocular OCT to describe novel features across a range of diseases. The repeatability of quantifying various parameters in the images acquired using the system will be assessed.
Read the detailed description
Imaging of the retina using OCT is the commonest ophthalmic imaging procedure worldwide - in 2011, it is estimated that more than 20 million retinal OCT images were obtained, more than the sum of all other ophthalmic imaging procedures combined).4 OCT is also used to image the anterior segment, particularly to measure corneal thickness, in glaucoma to measure the irido-corneal angle, 5 and more recently to measure cells in ocular inflammatory conditions. In addition, vitreous imaging may be useful to measure cells in the posterior chamber.
Most OCT systems are dedicated to retinal imaging or anterior segment imaging. Some commercial retinal scanners are capable of switching between anterior and posterior imaging modes with additional optical attachments, however anterior segment imaging performance is typically suboptimal in these instruments. A key feature of the Binocular OCT is that it can perform 'whole-eye' OCT imaging spanning from the eyelids to the posterior pole in a single instrument without the requirement of additional attachments, and in an automated way.
This study will determine whether the instrument can be used for patients with different eye diseases. The investigators anticipate recruiting approximately 100 participants with anterior eye conditions such as keratoconus, acute anterior uveitis, and pigment dispersion syndrome, in addition to approximately 100 participants with posterior segment eye conditions such as diabetic retinopathy, age-related macular degeneration, and glaucoma.
As this device can image many structures of the eye and with a greater depth range than most commercial OCT devices, it may be possible to visualise features not previously imaged with other devices such as vitreous imaging, or imaging of cells in the ocular inflammatory conditions. In this study, the prototype binocular OCT system will be used to describe novel features across a range of ocular diseases. Qualitative analyses of raw binocular OCT images will be performed (including assessments of retinal pathological features, corneal and anterior chamber morphology, lens status, iris dynamics, and ocular inflammatory cells). These parameters will be correlated with findings from other non-invasive ocular imaging previously obtained during routine clinical care. Although raw OCT images can be useful for diagnosis, quantitative data from the images are useful to monitor eye disease. Commercial OCT devices have built-in software packages to analyse OCT images to provide the clinician with parameters for detecting and monitoring eye disease. Quantitative analysis of binocular OCT images will be performed using MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
In addition, the ability to combine structural and functional assessments in the same instrument may permit better examinations of ophthalmic disease compared to separate clinical tests. This study will also permit future studies to be correctly powered.
- Conditions
- Eye Diseases, Eye Infections, Eye Inflammation
- Being tested
- Binocular OCT
- Keywords
- Optical Coherence Tomography, Automated, Binocular
- Medical subject headings
- Eye Diseases, Eye Infections, Endophthalmitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Binocular OCTDevice
Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
| Study group | Role | What they receive |
|---|---|---|
| Participants with eye disease | A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma. Receives: Device: Binocular OCT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Repeatability of the binocular OCY
The primary objective will be to assess the repeatability of quantifying various parameters in images acquired using a prototype binocular OCT system. This will be explored in different diseases.
Measured: 2 years
Secondary outcomes (1)
Comparison with other devices
The secondary objective will be to compare to other imaging modalities and describe novel features across a range of ocular diseases.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2018
- Study start22 May 2018
- Primary completion1 Mar 2020
- Study completion1 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Eye DiseasesStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03553017
- Sponsor's protocol ID
- 17/0839
- Status last verified
- Oct 2020
- First submitted
- 29 May 2018
- Last updated
- 19 Oct 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chopra R, Mulholland PJ, Dubis AM, Anderson RS, Keane PA. Human Factor and Usability Testing of a Binocular Optical Coherence Tomography System. Transl Vis Sci Technol. 2017 Aug 15;6(4):16. doi: 10.1167/tvst.6.4.16. eCollection 2017 Jul.
PubMed 28824827Walsh AC. Binocular optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2011 Jul;42 Suppl:S95-S105. doi: 10.3928/15428877-20110627-09.
PubMed 21790117
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single-Site Non-Interventional Exploratory Study Using a Prototype Binocular Optical Coherence Tomography System for Imaging of Ocular Disease
- ClinicalTrials.gov ID
- NCT03553017
- Acronym / sponsor ID
- 17/0839
- Conditions
- Eye Diseases, Eye Infections, Eye Inflammation
- Keywords
- Optical Coherence Tomography, Automated, Binocular
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Study start
- 22 May 2018 (actual)
- Primary completion
- 1 Mar 2020 (actual)
- Study completion
- 1 Mar 2020 (actual)
- First posted
- 12 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Optical coherence tomography (OCT) is an imaging modality, first described in 1991, that provides cross-sectional images of the eye in a non-invasive manner. OCT is analogous to ultrasonography but measures the "echoes" of light waves rather than sound and, as a result, generates extremely high-resolution images (~5 μm axial resolution). Although OCT has already proven revolutionary in ophthalmology, current OCT systems are large, expensive, and require skilled personnel for image acquisition and interpretation. Furthermore, current OCT systems are limited to examination of specific regions of single eyes - for example, separate devices are typically required for anterior segment (e.g., cornea) versus posterior segment (e.g., retina) imaging. A new form of OCT imaging has recently been developed - so-called "binocular" optical coherence tomography (OCT) (Envision Diagnostics, Inc., California).1,2 Binocular OCT addresses many of the short-comings of conventional OCT devices.
Binocular OCT extends the application of OCT devices beyond that of simple, cross- sectional imaging to a diverse array of diagnostic tests. The binocular design also removes the need for additional personnel to perform testing (i.e., the device can be self-operated in an automated manner), and allows for novel testing to be performed that is not possible with monocular imaging. In particular, binocular OCT devices have the potential to perform automated, quantitative pupillary measurements - an entirely novel application for this imaging modality, plus also adds a number of unique capabilities. In particular, binocular OCT removes the need for additional personnel to acquire the images by enabling patients to align the optical axes of the instrument with the optical axes of their own eyes. The system also employs recently developed "swept-source" lasers as its light source, allowing it to see deeper into the eye than conventional OCT systems. Finally, binocular OCT systems allow image capture from both eyes at the same time. This "simultaneous" ocular imaging extends the range of diagnostic testing possible, allowing for features such as pupillometry and ocular motility.
The greatly increased range of imaging for these lasers enables the entire depth of eye tissue to be captured in just a few sequences of images - so- called "whole eye" OCT or "OCT ophthalmoscopy".
In this study, the investigators aim to explore the unique imaging features of the binocular OCT to describe novel features across a range of diseases. The repeatability of quantifying various parameters in the images acquired using the system will be assessed.
Detailed description
Imaging of the retina using OCT is the commonest ophthalmic imaging procedure worldwide - in 2011, it is estimated that more than 20 million retinal OCT images were obtained, more than the sum of all other ophthalmic imaging procedures combined).4 OCT is also used to image the anterior segment, particularly to measure corneal thickness, in glaucoma to measure the irido-corneal angle, 5 and more recently to measure cells in ocular inflammatory conditions. In addition, vitreous imaging may be useful to measure cells in the posterior chamber.
Most OCT systems are dedicated to retinal imaging or anterior segment imaging. Some commercial retinal scanners are capable of switching between anterior and posterior imaging modes with additional optical attachments, however anterior segment imaging performance is typically suboptimal in these instruments. A key feature of the Binocular OCT is that it can perform 'whole-eye' OCT imaging spanning from the eyelids to the posterior pole in a single instrument without the requirement of additional attachments, and in an automated way.
This study will determine whether the instrument can be used for patients with different eye diseases. The investigators anticipate recruiting approximately 100 participants with anterior eye conditions such as keratoconus, acute anterior uveitis, and pigment dispersion syndrome, in addition to approximately 100 participants with posterior segment eye conditions such as diabetic retinopathy, age-related macular degeneration, and glaucoma.
As this device can image many structures of the eye and with a greater depth range than most commercial OCT devices, it may be possible to visualise features not previously imaged with other devices such as vitreous imaging, or imaging of cells in the ocular inflammatory conditions. In this study, the prototype binocular OCT system will be used to describe novel features across a range of ocular diseases. Qualitative analyses of raw binocular OCT images will be performed (including assessments of retinal pathological features, corneal and anterior chamber morphology, lens status, iris dynamics, and ocular inflammatory cells). These parameters will be correlated with findings from other non-invasive ocular imaging previously obtained during routine clinical care. Although raw OCT images can be useful for diagnosis, quantitative data from the images are useful to monitor eye disease. Commercial OCT devices have built-in software packages to analyse OCT images to provide the clinician with parameters for detecting and monitoring eye disease. Quantitative analysis of binocular OCT images will be performed using MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
In addition, the ability to combine structural and functional assessments in the same instrument may permit better examinations of ophthalmic disease compared to separate clinical tests. This study will also permit future studies to be correctly powered.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with eye disease | – | Device: Binocular OCTA maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
Key inclusion criteria (6 listed)
- Presence of ocular disease that can be imaged using optical coherence tomography
- Male or female, aged 18 years or older
- Ability to understand nature/purpose of the study and to provide informed consent
- Ability to undergo binocular OCT imaging
- Ability to follow instructions and complete the study
Key exclusion criteria (3 listed)
- Optical media opacity sufficient to preclude adequate ocular imaging with OCT
- Hearing impairment sufficient to interfere with hearing instructions
- Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Binocular OCTParticipants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.). | Device | Participants with eye disease |
Primary outcome
Repeatability of the binocular OCY
Time frame: 2 years
The primary objective will be to assess the repeatability of quantifying various parameters in images acquired using a prototype binocular OCT system. This will be explored in different diseases.
1 secondary outcome
Comparison with other devices
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2020.
- Background: PubMed 28824827Chopra R, Mulholland PJ, Dubis AM, Anderson RS, Keane PA. Human Factor and Usability Testing of a Binocular Optical Coherence Tomography System. Transl Vis Sci Technol. 2017 Aug 15;6(4):16. doi: 10.1167/tvst.6.4.16. eCollection 2017 Jul.
- Background: PubMed 21790117Walsh AC. Binocular optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2011 Jul;42 Suppl:S95-S105. doi: 10.3928/15428877-20110627-09.
Related trials for Eye Diseases
Active, not recruiting
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
Meibomian Gland Dysfunction, Dry Eye Disease
RecruitingPhase 3
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
Diabetic Macular Edema (DME)
RecruitingObservational study
Screening for Research Participants
Eye Diseases
RecruitingObservational study
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
Genetic Eye Disease
RecruitingObservational study
Adaptive Optics Retinal Imaging
Eye Diseases, Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Eye Diseases and Eye Infections, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Repeatability of the binocular OCY (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03553017, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2020; AzTrials last refreshed its copy on 3 Nov 2026.